Galderma Group AG GALD.SW
Composite 56/100; the shares have moved about 30% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 24/100 — a strong mark against it.
Growth ranks 89/100 — a strong point in its favour. Quality ranks 60/100 — a slight point in its favour. Momentum ranks 60/100 — a slight point in its favour.
Valuation ranks 24/100 — a strong mark against it. Income ranks 35/100 — a moderate mark against it.
What the company does Galderma Group AG is a global dermatology leader focused on injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio includes brands like Restylane, Cetaphil, Epiduo, and Soolantra, serving medical and consumer markets worldwide.
Key financials Revenue grew 24.8% with EPS up 129.1%. Margins are strong: gross 68.9%, operating 17.8%, net 11.7%. ROE is 7.7%, ROCE 15.6%, and ROA 4.2%. Debt/equity is 0.34 with net debt/EBITDA at 1.74.
Stock health Momentum is positive: +32.95% over 12m, +19.92% over 6m, and +11.91% over 3m. RSI(14) is 56.70. Sideravia scores: Quality 63.2, Growth 89.0, Momentum 75.5.
Price vs fair value The stock trades at a PREMIUM of 67.40% to our fair-value estimate of 57.65 and at a discount of 7.67% to the analyst 12-month target of 190.68. - Morgan Stanley bullish on Galderma on stronger Nemluvio growth outlook (Investing.com) - High forward P/E of 46.08 and PEG of 1.62 reflect premium valuation (Valuation percentile 20.3/100) - Analyst count of 18 supports near-term target of 190.68 (Analyst 12-month target 190.68)
Looking forward Forward P/E of 46.08 and PEG of 1.62 suggest valuation headwinds despite growth. Momentum remains robust, but rich multiples may limit upside unless growth accelerates further.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.